Australia markets close in 2 hours 48 minutes
  • ALL ORDS

    7,215.40
    -36.90 (-0.51%)
     
  • ASX 200

    6,963.10
    -32.10 (-0.46%)
     
  • AUD/USD

    0.7606
    -0.0017 (-0.23%)
     
  • OIL

    59.37
    +0.05 (+0.08%)
     
  • GOLD

    1,740.10
    -4.70 (-0.27%)
     
  • BTC-AUD

    78,739.53
    -1,228.30 (-1.54%)
     
  • CMC Crypto 200

    1,280.41
    +52.87 (+4.31%)
     
  • AUD/EUR

    0.6394
    -0.0007 (-0.11%)
     
  • AUD/NZD

    1.0821
    -0.0004 (-0.04%)
     
  • NZX 50

    12,480.08
    -94.27 (-0.75%)
     
  • NASDAQ

    13,845.05
    +86.55 (+0.63%)
     
  • FTSE

    6,915.75
    -26.47 (-0.38%)
     
  • Dow Jones

    33,800.60
    +297.00 (+0.89%)
     
  • DAX

    15,234.16
    +31.46 (+0.21%)
     
  • Hang Seng

    28,310.79
    -388.01 (-1.35%)
     
  • NIKKEI 225

    29,616.71
    -151.35 (-0.51%)
     

Emergent BioSolutions Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Emergent BioSolutions

Kaplan Fox & Kilsheimer LLP
·2-min read

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS).

On March 31, 2021, after market, reports emerged that Emergent BioSolutions had made errors in manufacturing 15 million doses of coronavirus vaccine for Johnson & Johnson. The New York Times, for example, reported that Emergent BioSolutions, a manufacturing partner to both Johnson & Johnson and AstraZeneca, had “accidentally conflated the ingredients for two different coronavirus vaccines several weeks ago, ruining about 15 million doses of Johnson & Johnson’s vaccine and forcing regulators to delay authorization of the plant’s production lines.” Additionally, according to Yahoo News, Senior Biden administration health officials “knew two weeks ago that a Johnson & Johnson contractor's production problems could delay delivery of a significant number of future vaccine doses.”

Then, on April 1, 2021, Emergent BioSolutions published a statement admitting that it had identified and disposed of a batch of drug substance that did not meet specifications.

Following this news, Emergent BioSolutions’ common stock fell $12.45 per share, or 13.4%, to close at $80.46 per share on heavy trading volume.

If you purchased or otherwise acquired Emergent BioSolutions securities and would like to discuss our investigation, please contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this investigation, your rights, or your interests, please contact:

Frederic S. Fox
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(646) 315-9003
E-mail: ffox@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com